Hepatitis B Pre and Post Vaccination Testing and Non-Response to Vaccination

> Francisco Averhoff, M.D., M.P.H. National Immunization Program Centers for Disease Control and Prevention Atlanta, GA fma0@cdc.gov



Characteristics of Hepatitis B Vaccine

- Highly immunogenic: > 95% response rate
- Excellent safety profile, few contraindications
- Can be administered to immune or HBV infected individuals w/o concern
- Reliable testing for infection and immunity available



Serologic Tests for Hepatitis B

Serologic Test

Interpretation

HBsAg + HBc-AB

Infection: acute or chronic

HBc-AB + HBs-AB

Immunity: Natural



Immunity: Vaccine



Pre-Vaccination Screening

- Not Routinely Recommended
- Purpose: Identify infected and/or immune individuals
- Defer Immunization (infected and immune)
- Refer for counseling & treatment (infected)



Pre-Vaccination Serologic Testing

Not indicated for infant and children


Maybe considered for adult/high risk

Cost effective for adult/high risk?


- Cost of vaccine
- Cost of serologic testing
- Prevalence of infection (HBc-Ab) in population
- Compliance of individuals– always administer first dose at time of testing!



Prevalence of HBV Infection, by Age, and Cost Effectiveness of Pre-Vaccination Testing



Immunogenicity of hepatitis B vaccine by Age



Risk Factors for non-response to HB vaccine

- Older age
- Immunodeficiency
- Chronic Illness
- Smoking
- Obesity



Post-Vaccination Screening

- > 95% seroconvert after 3 doses
 immune (HBs-Ab+)
- Testing 1-2 months following 3rd dose

 False-negative test (Hbs-Ab neg) possible after 6 months
- Quantitative HBs-Ab (best, if available)
 2 10 mIU/ml HBs-Ab



Post-Vaccination Serologic Testing

- Not Routinely Recommended
- May be considered:
 Infant of HBsAg+ mother (infected/immune)
 - High Risk for non-response and infection
 - HCWs



Post-Vaccination Screening

Management of Infants of HBsAg+ Mothers:

- Test at 9 months of age-
 - R/O possible late infection or
 - R/O passive immunity, if administer HBIG



Post-Vaccination Screening

Management of Non-Responders:

• Test 1-2 months after 3rd dose

 May administer repeat 3 dose series –0,1,6 months

Retest after completing repeat series



Management of Non-responders

- May administer an additional 3 doses on same schedule (0,1,6 months)
- 30% respond after 1 additional dose
- 50% respond after 3 additional doses




Persistent non-Responders

- < 5% do not develop antibody</p>
- May be non-responder or hyporesponder"
- "May be Chronic HBV (HBsAg+); will not respond to vaccine
- If exposed, should administer HBIG (if available)



Expected Results of Postvaccination testing



Management of Non-responders: Program Considerations

- 95% of healthy adults immune after 3 doses
- Need to test 100% to identify 5% of nonresponders
- 50% of non-responders seroconvert (2.5% of total population) with 3 additional doses
- Little Potential Benefit: 95% + 2.5% = 97.5%!





